Cardiorenal sydrome in dogs: the investigation for control measures

Authors

  • Marina Martins de Oliveira Universidade Federal de Lavras
  • Lorena Lorraine Alves Furtado Universidade Federal de Lavras
  • Claudine Botelho de Abreu Universidade Federal de Lavras
  • Tatiana Schulien Universidade Vale do Rio Verde - Três Corações
  • Ana Maria Barcelos Guerra Pinto University of Lincoln
  • Luiz Eduardo Duarte de Oliveira Universidade Federal de Lavras
  • Mariana de Resende Coelho Universidade Federal de Lavras
  • Ruthnéa Aparecida Lázaro Muzzi Universidade Federal de Lavras

DOI:

https://doi.org/10.35172/rvz.2019.v26.383

Keywords:

cardiopathy, dogs, nephropathy, anemia.

Abstract

The physiopathological relationship between the kidneys and the heart in the disease, known as cardiorenal syndrome (CRS), involves disorders of the heart and kidneys, since acute or chronic dysfunction in one organ can induce acute or chronic dysfunction of the other. In Veterinary Medicine, 5 subtypes of cardiorenal syndrome are described: acute cardiorenal, chronic cardiorenal, acute renocardial, chronic and secondary renocardial. Anemia is a common finding in dogs with cardiac and renal dysfunction, characterizing the so-called cardiorenal anemia syndrome. The mechanisms involved in the pathophysiology of the cardiorenal syndrome involve not only hemodynamic changes and activation of neurohormonal systems, but also the activation of compensatory mechanisms of the organism itself, which end up contributing to worsening cardiac and renal function, leading to the development of CRS. The great challenge found in Veterinary Medicine is related to the early diagnosis of this syndrome and, mainly, to the correct therapeutic management, since that the therapy of the cardiopathy can deteriorate the renal function, and vice versa. Therefore, it is important to understand how the pathophysiology of one disease can impact the function of the other organ. The present work aims to bring a complete approach to the pathophysiology, diagnosis and treatment of cardiorenal syndrome in dogs.

References

(1) Athwani V, Bhargava M, Chanchlani R, Mehta AJ. Incidence and outcome of acute cardiorenal syndrome in hospitalized children. Indian J Pediatr. 2017;84(6):420-4. doi: 10.1007/s12098-017-2307-3.

(2) Pouchelon JL, Atkins CE, Bussadori C, Oyama MA, Valden SL, Bonagura JD, Chetboul V, Cowgill LD, Elliot J, Francey T, Grauer GF, Fuentes VL, Moise NS, Polzin DJ, Van Dongen AM, Van Israël N. Cardiovascular-renal axis disorders in the domestic dog and cat: a veterinary consensus statement. J Small Anim Pract. 2015;56(9):537-52. doi: 10.1111/jsap.12387.

(3) Smyth A, Ronco C, Garovic VD. Preeclampsia: a cardiorrenal syndrome in pregnancy. Curr Hypertens Rep. 2017;19(2):15. doi: 10.1007/s11906-017-0714-5.

(4) Martinelli E, Locatelli C, Bassis S, Crosara S, Paltrinieri S, Scarpa P, Spalla I, Zanaboni AM, Quintavalla C, Brambilla P. Preliminary investigation of cardiovascular –renal disorders

in dogs with chronic mitral valve disease. J Vet Intern Med. 2016;30:1612-8. doi: 10.1111/jvim.14524.

(5) Keller SP, Kovacevic A, Howard J, Schweighauser A, Francey T. Evidence of cardiac injury and arrhythmias in dogs with acute kidney injury. J Small Anim Pract. 2016;57(8):402-8. doi: 10.1111/jsap.12495.

(6) Homma T, Sonoda H, Manabe K, Arai K, Mizuno M, Sada T, Ikeda, M. Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome. Am J Physiol Renal Physiol. 2012;302(6):50-67. doi: 10.1152/ajprenal.00494.2011.

(7) Núñes J, Miñana G, Santas E, Bertomeu-González V. Cardiorenal syndrome in acute heart failure: revisiting paradigms. Rev Esp Cardiol 2015;68(5):426-35. doi: 10.1016/j.rec.2014.10.016.

(8) Nicolle AP, Chetboul V, Allerheiligen T, Pouchelon JL, Gouni V, Tessier-Vetzel D, Sampedrano CC, Lefebvre HP. Azotemia and glomerular filtration rate in dogs with chronic valvular disease. J Vet Intern Med. 2007;21:943–9. doi: 10.1111/j.1939-1676.2007.tb03047.x

(9) Ronco C, Maisel A. Volume overload and cardiorenal syndromes. Congest Heart Fail. 2010;16(4):1-4. doi: 10.1111/j.1751-7133.2010.00176.x.

(10) Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, Kelly DJ, Krum H. Cronic kdney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 2012;7(7):1-10. doi: 10.1371/journal.pone.0041281.

(11) Virzi GM, Clemente A, Cal M, Brocca A, Day S, Pastori S, Bolin C, Vescovo G, Ronco C. Oxidative stress: dual pathway induction in cardiorrenal syndrome type 1 pathogenesis. Oxid Med Cell Longev. 2015;2015:1-9. doi: 10.1155/2015/391790.

(12) Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101(1):129-137. doi: 10.1016/j.mcna.2016.08.009.

(13) Sims CR, Singh SP, Mu S, Gokden N, Zakaria D, Nguyen TC, Mayeux PR. Rolipram improves outcome in a rat modelo of infant sepsis-induced cardiorenal syndrome. Front Pharmacol. 2017; 8(237):1-4. doi: 10.3389/fphar.2017.00237.

(14) Pereira, C S, Muzzi RAL, Figueiredo VC, Oberlender G, Lacreta Júnior ACC, Leomil Neto M, Oliveira MM. Troponin I as a biomarker of cardiac injury in dogs with sepsis. Arq. Bras. Med. Vet. Zootec. 2016;68(4):919-26. doi: 10.1590/1678-4162-8696.

(15) Yu, IBY, Huang, HP. Prevalence and prognosis of anemia in dogs with degenerative mitral valve disease. Biomed Res Int. 2016;2016:1-5. doi: 10.1155/2016/4727054.

Published

2019-12-17

How to Cite

1.
de Oliveira MM, Furtado LLA, de Abreu CB, Schulien T, Pinto AMBG, de Oliveira LED, Coelho M de R, Lázaro Muzzi RA. Cardiorenal sydrome in dogs: the investigation for control measures. RVZ [Internet]. 2019 Dec. 17 [cited 2024 Nov. 21];26:1-7. Available from: https://rvz.emnuvens.com.br/rvz/article/view/383

Issue

Section

Review Articles